Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Aug 15;2012(8):CD004643.
doi: 10.1002/14651858.CD004643.pub3.

Blood pressure lowering efficacy of alpha blockers for primary hypertension

Balraj S Heran  1 , Brandon P Galm, James M Wright
Affiliations
Meta-Analysis

Blood pressure lowering efficacy of alpha blockers for primary hypertension

Balraj S Heran et al. Cochrane Database Syst Rev. .

Abstract

Background: Alpha blockers are occasionally prescribed for hypertension so it is important to determine and compare their effects on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE).

Objectives: To quantify the dose-related systolic and/or diastolic BP lowering efficacy of alpha blockers versus placebo in the treatment of primary hypertension.

Search methods: For the updated review, we searched CENTRAL (The Cochrane Library 2012, Issue 4), MEDLINE (1946 to May 2012), EMBASE (1980 to May 2012) and reference lists of articles.

Selection criteria: Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of fixed-dose monotherapy with an alpha blocker compared with placebo for a duration of 3 to 12 weeks in patients with primary hypertension.

Data collection and analysis: Two authors independently assessed the risk of bias and extracted data. Study authors were contacted for additional information. WDAE information was collected from the trials.

Main results: Only 10 trials evaluated the dose-related trough BP lowering efficacy of 4 different alpha blockers in 1175 participants with a baseline BP of 155/101 mm Hg. The data do not suggest that any one alpha blocker is better or worse at lowering BP. The best but unsatisfactory estimate of the trough BP lowering efficacy for alpha blockers is -8/-5 mmHg.

Authors' conclusions: Based on the limited number of published RCTs, the BP lowering effect of alpha blockers is modest; the estimate of the magnitude of trough BP lowering of -8/-5 mmHg is likely an overestimate. There are no clinically meaningful BP lowering differences between different alpha blockers. The review did not provide a good estimate of the incidence of harms associated with alpha blockers because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
PRISMA flow diagram
1.1
1.1. Analysis
Comparison 1 Doxazosin vs Placebo, Outcome 1 Change in trough SBP.
1.2
1.2. Analysis
Comparison 1 Doxazosin vs Placebo, Outcome 2 Change in trough DBP.
1.3
1.3. Analysis
Comparison 1 Doxazosin vs Placebo, Outcome 3 Change in peak SBP.
1.4
1.4. Analysis
Comparison 1 Doxazosin vs Placebo, Outcome 4 Change in peak DBP.
1.5
1.5. Analysis
Comparison 1 Doxazosin vs Placebo, Outcome 5 Change in trough heart rate.
1.6
1.6. Analysis
Comparison 1 Doxazosin vs Placebo, Outcome 6 Change in peak heart rate.
1.7
1.7. Analysis
Comparison 1 Doxazosin vs Placebo, Outcome 7 Total withdrawals due to adverse effects.
2.1
2.1. Analysis
Comparison 2 Prazosin vs Placebo, Outcome 1 Change in trough SBP.
2.2
2.2. Analysis
Comparison 2 Prazosin vs Placebo, Outcome 2 Change in trough DBP.
2.3
2.3. Analysis
Comparison 2 Prazosin vs Placebo, Outcome 3 Change in trough heart rate.
2.4
2.4. Analysis
Comparison 2 Prazosin vs Placebo, Outcome 4 Total withdrawals due to adverse effects.
3.1
3.1. Analysis
Comparison 3 Terazosin vs Placebo, Outcome 1 Change in trough SBP.
3.2
3.2. Analysis
Comparison 3 Terazosin vs Placebo, Outcome 2 Change in trough DBP.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Abraham 1985 {published data only}
    1. Abraham P A, Halstenson C E, Matzke G R, Napier J L, Keane W F. Antihypertensive therapy with once‐daily administration of terazosin, a new alpha 1‐adrenergic‐receptor blocker. Pharmacotherapy 1985;5(5):285‐9. - PubMed
    1. Dauer A D. Terazosin: an effective once‐daily monotherapy for the treatment of hypertension. American Journal of Medicine 1986;80(5B):29‐34. - PubMed
    1. Deger G. Comparison of the safety and efficacy of once‐daily terazosin versus twice‐daily prazosin for the treatment of mild to moderate hypertension. American Journal of Medicine 1986;80(5B):62‐7. - PubMed
    1. Deger G. Effect of terazosin on serum lipids. American Journal of Medicine 1986;80(5B):82‐5. - PubMed
    1. Luther R R. Terazosin: a new antihypertensive agent with favorable effects on lipids. International Journal of Clinical Pharmacology, Therapy, & Toxicology 1989;27(7):313‐9. - PubMed
Cubeddu 1988 {published data only}
    1. Cubeddu L X, Pool J L, Bloomfield R, Klotman P E, Pickering B I, Wombolt D G, et al. Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension. American Journal of Hypertension 1988;1(2):158‐67. - PubMed
Dauer 1986, Study M81‐059 {published data only}
    1. Dauer A D. Terazosin: an effective once‐daily monotherapy for the treatment of hypertension. American Journal of Medicine 1986;80(5B):29‐34. - PubMed
    1. Deger G. Comparison of the safety and efficacy of once‐daily terazosin versus twice‐daily prazosin for the treatment of mild to moderate hypertension. American Journal of Medicine 1986;80(5B):62‐7. - PubMed
    1. Deger G. Effect of terazosin on serum lipids. American Journal of Medicine 1986;80(5B):82‐5. - PubMed
    1. Luther R R. Terazosin: a new antihypertensive agent with favorable effects on lipids. International Journal of Clinical Pharmacology, Therapy, & Toxicology 1989;27(7):313‐9. - PubMed
    1. Luther R R, Glassman H N, Jordan D C, Sperzel W D. Efficacy of terazosin as an antihypertensive agent. American Journal of Medicine 1986;80(5B):73‐6. - PubMed
Gillenwater 1995 {published data only}
    1. Gillenwater J Y, Conn R L, Chrysant S G, Roy J, Gaffney M, Ice K, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double‐blind, placebo‐controlled, dose‐response multicenter study. Journal of Urology 1995;154(1):110‐5. - PubMed
Harder 1994 {published data only}
    1. Harder S, Thurmann P. Concentration/effect relationship of bunazosin, a selective alpha 1‐adrenoceptor antagonist in hypertensive patients after single and multiple oral doses. International Journal of Clinical Pharmacology & Therapeutics 1994;32(1):38‐43. - PubMed
Mersey 1984 {published data only}
    1. Dauer A D. Terazosin: an effective once‐daily monotherapy for the treatment of hypertension. American Journal of Medicine 1986;80(5B):29‐34. - PubMed
    1. Deger G. Comparison of the safety and efficacy of once‐daily terazosin versus twice‐daily prazosin for the treatment of mild to moderate hypertension. American Journal of Medicine 1986;80(5B):62‐7. - PubMed
    1. Deger G. Effect of terazosin on serum lipids. American Journal of Medicine 1986;80(5B):82‐5. - PubMed
    1. Luther R R. Terazosin: a new antihypertensive agent with favorable effects on lipids. International Journal of Clinical Pharmacology, Therapy, & Toxicology 1989;27(7):313‐9. - PubMed
    1. Luther R R, Glassman H N, Jordan D C, Sperzel W D. Efficacy of terazosin as an antihypertensive agent. American Journal of Medicine 1986;80(5B):73‐6. - PubMed
Os 1999 {published data only}
    1. Os I, Stokke H P. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Pressure 1999;8(3):184‐91. - PubMed
    1. Os I, Stokke H P. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild‐to‐moderate hypertension. Doxazosin Investigators' Study Group. Journal of Cardiovascular Pharmacology 1999;33(5):791‐7. - PubMed
Schnaper 1975, Study 2 {published data only}
    1. Schnaper H W, Oberman A. Double‐blind studies of the clinical effectiveness of prazosin. Postgraduate Medicine 1975;Spec No:81‐7. - PubMed
Singleton 1989 {published data only}
    1. Singleton W, Dix R K, Monsen L, Moisey D, Levenstein M, Bottiglieri D F, et al. Efficacy and safety of Minipress XL, a new once‐a‐day formulation of prazosin. American Journal of Medicine 1989;87(2A):45S‐52S. - PubMed
Weber 1991 {published data only}
    1. Weber M A, Cheung D G, Laddu A R, Luther R R. Antihypertensive dose‐response relationships: studies with the selective alpha 1‐blocking agent terazosin. American Heart Journal 1991;122(3 Pt 2):905‐10. - PubMed

References to studies excluded from this review

Achari 2000 {published data only}
    1. Achari R, Hosmane B, Bonacci E, O'Dea R. The relationship between terazosin dose and blood pressure response in hypertensive patients. Journal of Clinical Pharmacology 2000;40:1166‐72. - PubMed
Ames 1989 {published data only}
    1. Ames R P, Chrysant S G, Gonzalez F, Schnaper H W, Spann S, Velasquez M T. Effectiveness of doxazosin in systemic hypertension. American Journal of Cardiology 1989;64(3):203‐8. - PubMed
Ames 1989a {published data only}
    1. Ames R P, Kiyasu J Y. Alpha‐1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins. Journal of Clinical Pharmacology 1989;29(2):123‐7. - PubMed
Aronow 1977 {published data only}
    1. Aronow W S, Tobis J, Hughes D, Siegel J, Easthope J. Comparison of trimazosin and methyldopa in hypertension. Clinical Pharmacology & Therapeutics 1977;22(4):425‐9. - PubMed
Aronow 1978 {published data only}
    1. Aronow W S, Oberman A, Pool P E, Schnaper H W, Seagren S C, Tobis J, Hughes D, Siegel J, Easthope J. Effect of trimazosin, methyldopa, and placebo on hypertension. Current Therapeutic Research 1978;23(4):448‐54.
Baez 1986 {published data only}
    1. Baez M A, Garg D C, Jallad N S, Weidler D J. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol. British Journal of Clinical Pharmacology 1986;21 Suppl 1:63S‐7S. - PMC - PubMed
Chrysant 1981 {published data only}
    1. Chrysant S G, Miller R F, Brown J L, Danisa K. Long‐term hemodynamic and metabolic effects of trimazosin in essential hypertension. Clinical Pharmacology & Therapeutics 1981;30(5):600‐4. - PubMed
Cohen 1987 {published data only}
    1. Cohen A. Placebo‐controlled study of once‐daily administration of terazosin to patients with mild‐to‐moderate hypertension. Current Therapeutic Research, Clinical & Experimental 1987;41(1):105‐13.
Courtney 2003 {published data only}
    1. Courtney C H, McCance D R, Atkinson A B, Bassett J, Ennis C N, Sheridan B, et al. Effect of the alpha‐adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism: clinical and experimental 2003, issue 9:1147‐52. - PubMed
Gould 1981 {published data only}
    1. Gould B A, Mann S, Davies A B, Altman D G, Raftery E B. Can placebo therapy influence arterial blood pressure?. Clinical Science 1981;61 Suppl 7:487s‐90s. - PubMed
Materson 1993 {published data only}
    1. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J. Single‐drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. New England Journal of Medicine 1993;328(13):914‐21. - PubMed
Mroczek 1974 {published data only}
    1. Mroczek W J, Fotiu S, Davidov M E, Finnerty F A Jr. Prazosin in hypertension: a double‐blind evaluation with methyldopa and placebo. Current Therapeutic Research, Clinical & Experimental 1974;16(8):769‐77. - PubMed
Nash 1987 {published data only}
    1. Nash D T, Schonfeld G, Reeves R L, Black H, Weidler D J. A double‐blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension. American Journal of Cardiology 1987;59(14):87G‐90G. - PubMed
Romero 1992 {published data only}
    1. Romero E, Angeli M, Velasco M, Azar E, Bueno O, Lema G, et al. Double‐blind placebo‐controlled trial of terazosin effect on blood pressure and urinary output of dopamine in hypertensive patients. Journal of Clinical Pharmacology 1992;32(9):816‐21. - PubMed
Shionoiri 1997 {published data only}
    1. Shionoiri H, Ashino K, Yamanaka K, Shindo K, Hiroto S, Arita T. Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. Clinical Therapeutics 1997;19(3):527‐36. - PubMed
Smyth 1988 {published data only}
    1. Smyth P, Pringle S, Jackson G, Lorimer A R. 24‐hour control of blood pressure by once daily doxazosin: a multicentre double‐blind comparison with placebo. European Journal of Clinical Pharmacology 1988;34(6):613‐8. - PubMed
Svetkey 1988 {published data only}
    1. Svetkey L P, Brobyn R, Deedwania P, Graham R M, Morganroth J, Klotman P E. Double‐blind comparison of doxazosin, nadolol, and placebo in patients with mild‐to‐moderate hypertension. Current Therapeutic Research 1988;43(5):969‐78.
Torvik 1986 {published data only}
    1. Torvik D, Madsbu H P. Multicentre 12‐week double‐blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. British Journal of Clinical Pharmacology 1986;21 Suppl 1:69S‐75S. - PMC - PubMed
Venter 1991 {published data only}
    1. Venter CP, Venter HL, Muntingh GL. The effect of enalapril and prazosin on mild to moderate hypertension in black Africans. Results of a clinical trial [Die Effekte Van Enalapril En Prasosien Op Geringe Tot Matige Hipertensie in Swart Suid‐Afrikaners. Resultate Van 'N Kliniese Proef]. South African Medical Journal 1991;80:324‐6. - PubMed
Yasunari 2006 {published data only}
    1. Yasunari K, Matsui T, Maeda K, Nakamura M, Watanabe T, Kiriike N. Anxiety‐induced plasma norepinephrine augmentation increases reactive oxygen species formation by monocytes in essential hypertension. American Journal of Hypertension 2006;19(6):573‐8. - PubMed

Additional references

ALLHAT 2000
    1. Davis B R, Furberg C D, Wright J T, Cutler J A, Alderman M, Black H, Cushman W, et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT). Journal of the American Medical Association 2000;283(15):1967‐75. - PubMed
Bucher 1997
    1. Bucher H C, Guyatt G H, Griffith L E, Walter D. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683‐91. - PubMed
Cochrane Handbook 2008
    1. Higgins J P T, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration 2008. Available from www.cochrane‐handbook.org.
Dauer 1986
    1. Dauer A D. Terazosin: an effective once‐daily monotherapy for the treatment of hypertension. American Journal of Medicine 1986;80(5B):29‐34. - PubMed
Heran 2008a
    1. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003823.pub2] - DOI - PMC - PubMed
Heran 2008b
    1. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003822.pub2] - DOI - PMC - PubMed
Musini 2008
    1. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD007066.pub2] - DOI - PubMed
Song 2003
    1. Song F, Altman D G, Glenny A M, Deeks J J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta‐analyses. British Medical Journal 2003;326:472‐76. - PMC - PubMed
Wright 2009
    1. Wright J M, Musini V M. First‐line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources